Abstracts tagged "Disease Activity"

Abstract Number: 114 • 2014 ACR/ARHP Annual Meeting
Treat-to-Target (T2T) and Measuring Outcomes in RA Care: a 2014 Longitudinal Survey of US Rheumatologists
John J. Cush¹ and Jeffrey R. Curtis², ¹Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ²University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Changes in US rheumatologic practice for rheumatoid arthritis (RA) patients in the past decade have been influenced by novel therapies, increasing disease metric use…
Abstract Number: 2636 • 2014 ACR/ARHP Annual Meeting
Vitamin D Improves Endothelial Function in Patients with Clinically Stable Systemic Lupus Erythematosus (SLE)
John A. Reynolds¹, David W. Ray², Terence O'Neill³, Yvonne Alexander⁴ and Ian N. Bruce^5,6, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, ²Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ⁴Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose SLE patients have an increased risk of cardiovascular disease (CVD). Vitamin D deficiency has been associated with both CVD risk factors and subclinical CVD…
Abstract Number: 2416 • 2014 ACR/ARHP Annual Meeting
Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice
Regan Arendse¹, John Kelsall², J. Antonio Avina-Zubieta³, Philip Baer⁴, Erica Weinberg⁴, Jude Rodrigues⁵, Algis Jovaisas⁶, Isabelle Fortin⁷, Maqbool Sheriff⁸, Majed M. Khraishi⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Susan Otawa¹² and Allen J Lehman¹², ¹University of Saskatchewan, Saskatoon, SK, Canada, ²The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Scarborough, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶194 Main Street, University of Ottawa, Ottawa, ON, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose This analysis aimed to describe the pattern of specific joint involvement (tender and/or swollen) pre- and post-TNFi treatment and the impact of specific joint…
Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting
Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…
Abstract Number: 1386 • 2014 ACR/ARHP Annual Meeting
Disease Flares during 10 Year Follow-up in Patients with Rheumatoid Arthritis Are Associated with Joint Damage Progression and Disability
I.M. Markusse¹, L. Dirven², Y.P. Goekoop-Ruiterman³, P.a. van der Lubbe⁴, A.J. Peeters⁵, P.J.S.M. Kerstens⁶, W.F. Lems^7,8, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁸Rheumatology, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: Disease flares frequently occur in patients with rheumatoid arthritis (RA). It has been suggested that these may spontaneously remit, in which case targeted treatment…
Abstract Number: 1039 • 2014 ACR/ARHP Annual Meeting
Interleukin-20 Is Triggered By TLR Ligands and Associates with Rheumatoid Arthritis Disease Activity
Ladislav Senolt¹, Klara Prajzlerova¹, Hana Hulejova², David Veigl³, Karel Pavelka¹ and Jiri Vencovsky¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³1st Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and subsequent joint damage with systemic manifestations. Interleukin-20 (IL-20) has been…
Abstract Number: 666 • 2014 ACR/ARHP Annual Meeting
Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE: The Atacicept Phase IIb Trial Design
Joan T. Merrill¹, Yong Li², Stephen D. Wax³ and Christopher Tehlirian⁴, ¹Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²R&D Global BioStatistics, EMD Serono, Billerica, MA, ³Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, ⁴EMD Serono, Rockland, MA
Background/Purpose Increases in background treatment in SLE trials lead to high placebo group responses in patients with moderate but not those with high disease activity…
Abstract Number: 390 • 2014 ACR/ARHP Annual Meeting
Prevalence and Correlates of Patient-Physician Discordance in Early Rheumatoid Arthritis
John M. Davis III¹, Cynthia S. Crowson², Tim Bongartz¹, Clement J. Michet¹, Eric L. Matteson¹ and Sherine E. Gabriel³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) sometimes rate their global disease activity differently than their rheumatologists. Previous studies describing this ‘discordance’ have primarily included patients…
Abstract Number: 101 • 2014 ACR/ARHP Annual Meeting
Country of Residence and Its Wealth Determine Disease Activity Levels in RA: Results from Multi-National Study Across 17 Countries (COMORA)
Polina Putrik^1,2, Sofia Ramiro³, Andras Keszei⁴, Ihsane Hmamouchi⁵, Maxime Dougados⁶, Till Uhlig⁷, Tore K. Kvien⁷ and Annelies Boonen⁸, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Health Promotion, Maastricht University, Maastricht, Netherlands, ³Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ⁴Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ⁵Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁶Cochin Hospital, Paris Descartes University, Paris, France, ⁷Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose Socio-economic (SE) inequalities in health persist both between and within countries and even increased in the recent years. Therefore, it is important to explore…
Abstract Number: 2634 • 2014 ACR/ARHP Annual Meeting
A Signal of Improvement in Lupus Disease Activity at 3 Months Predicts Further Valid Improvement at 6 Months
Zahi Touma¹, Dafna D. Gladman², Dominique Ibanez¹ and Murray B. Urowitz², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: In patients with active disease, physicians look for an early signal in response to treatment to guide their therapeutic decisions. Systemic Lupus…
Abstract Number: 2430 • 2014 ACR/ARHP Annual Meeting
The Impact of Inadequate Health Literacy on Disease Activity in Patients with Rheumatoid Arthritis
Maria Celeste Orozco¹, Maria Florencia Marengo², Christian A. Waimann², Ana Inés Marcos³, Amelia Granel³, Sofia Velez⁴, Federico Zazzetti⁵, Juan C. Barreira⁶, Paula Kohan⁷, Oscar L. Rillo⁸, María Victoria Collado⁹, Graciela Gómez¹⁰, Ricardo V. Juárez¹¹, Veronica Lencina¹², Andrea D'Orazio¹³, Gustavo Rodriguez Gil¹³, Mariana Salcedo¹⁴ and Gustavo Citera¹⁵, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology, Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, ⁴Rheumatology, Hospital Britanico, Buenos Aires, Argentina, ⁵Hospital Britanico, Buenos Aires, Argentina, ⁶Rheumatology, British Hospital, Buenos Aires, Argentina, ⁷rheumatology, Hospital Gral. de agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁸Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁹Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ¹⁰Diaz Colodrero 2537 8° A, Insituto de Investigaciones Medicas de la UBA, Capital Federal, Argentina, ¹¹Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹²Rheumatology section, Hospital Señor del Milagro, Salta, Argentina, ¹³rheumatology, Hospital Municipal de agudos Dr. Leonidas Lucero, Bahía Blanca, Argentina, ¹⁴Consultorio Privado, San Nicolás, Argentina, ¹⁵Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Health literacy is the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions. It is being…
Abstract Number: 1902 • 2014 ACR/ARHP Annual Meeting
Utility of Glyca, a Novel Inflammatory Marker, for Assessment of Rheumatoid Arthritis Disease Activity
Michelle Ormseth¹, Cecilia P. Chung², Joseph F. Solus³, Annette M. Oeser³, Margery A. Connelly⁴, Jim Otvos⁴ and C Michael Stein³, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴LipoScience, Inc., Raleigh, NC
Background/Purpose GlycA is a novel inflammatory biomarker measured from the nuclear magnetic resonance (NMR) spectra obtained for lipoprotein particle analysis. It represents a distinct peak…
Abstract Number: 1375 • 2014 ACR/ARHP Annual Meeting
Educational Level and Not Ethnicity an Important Determinant of Disease Progression in Patients with Rheumatoid Arthritis
Sharon Dowell¹, Gail S. Kerr², Yusuf Yazici³, Christopher Swearingen⁴, Mercedes Quinones⁵, Luis R. Espinoza⁶, Edward L. Treadwell⁷, Theresa Lawrence-Ford⁸, Yvonne Sherrer⁹, Angelia Mosley-WIlliams¹⁰, Ignacio Garcia-Valladares¹¹, Rodolfo Perez Alamino¹², Chunqiao Luo¹³, Akgun Ince¹⁴, Adrian Godoy¹ and John Amatruda¹⁵, ¹Division of Rheumatology, Howard University, Washington, DC, ²Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR, ⁵Division of Rheumatology, Howard University Hospital, Washington, DC, ⁶Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁷Dept Medicine Div of Rheum, East Carolina University, Greenville, NC, ⁸North Georgia Rheumatology Group, PC, Lawrenceville, GA, ⁹Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ¹⁰Rheumatology, Detroit VAMC, Detroit, MI, ¹¹Immunology and Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ¹²internal Medicine, LSUHSC, New Orleans, LA, ¹³University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁴Arthitis Consultants Inc, St. Louis University, St. Louis, MO, ¹⁵Rheumatology, Howard University, Washington, DC
Background/Purpose: Formal educational level is often used as a surrogate for socioeconomic status and in patients with rheumatoid arthritis (RA), low levels have been associated…
Abstract Number: 1002 • 2014 ACR/ARHP Annual Meeting
Global Transcriptome Analysis in Osteoarthritic Cartilage Reveals Significant Differential Gene Expression and Associations with Histologic Disease Progression
Matlock A. Jeffries^1,2, Madison Donica³, Anand Annan⁴, Michael Stevenson⁵, Mary Beth Humphrey^6,7, Judith A. James^6,8 and Amr H. Sawalha⁹, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Pathol;ogy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Rheumatology/Immunology/Arthritis Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Osteoarthritis (OA) is the leading cause of chronic disability affecting 40% of individuals over the age of 70 and costing $128 billion annually in…
Abstract Number: 622 • 2014 ACR/ARHP Annual Meeting
Gut Microbiota Variations Correlate with Disease Activity in Spondyloarthritis (SpA) and Rheumatoid Arthritis (RA)
Julien Tap^1,2, Jad Abou-Ghantous¹, Ariane Leboime³, Roula Said Nahal³, Philippe Langella¹, Henri-Jean Garchon⁴, Gilles Chiocchia⁵, Jean-Pierre Furet¹ and Maxime Breban^3,4, ¹UMR INRA-AgroParisTech 1319, Equipe ProbiHote, MICALIS Institute, National Institute for Agronomical research (INRA), Jouy-en-Josas, France, ²Metagenopolis, INRA, Jouy-en-Josas, France, ³Service de Rhumatologie, Hopital Ambroise Pare, Boulogne-Billancourt, France, ⁴INSERM U987, Faculté des Sciences de la Santé Simone Veil, Montigny-le-Bretonneux, France, ⁵Versailles Saint Quentin en Yvelines University, INSERM U987, UFR des Sciences de la Santé, Montigny-le-Bretonneux, France
Background/Purpose Inflammatory bowel diseases (IBD) are associated with changes in microbiota which may be responsible for sustained gut inflammation and/or a consequence of it. Whether…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].